Abstract: The present invention relates to a vaccine capable to induce production of antibodies directed to PCSK9 in vivo.

Abstract: Disclosed is a method for detecting aSyn-specific antibodies in a biological sample, comprising the following steps: —contacting the sample with aSyn-comprising-aggregates and allowing the aSyn-specific antibodies to bind to the aSyn-comprising-aggregates, and —detecting the aSyn-specific antibodies bound to the aSyn-comprising-aggregates by a single particle detection technique, preferably by fluorescence activated cell sorting (FACS).

Abstract: Disclosed is a method for diagnosing Alzheimer's disease (AD) wherein A?-specific antibodies in a biological sample of a person that is suspected of having AD are detected comprising the following steps: —contacting the sample with A?-aggregates or with particles having A?-aggregate like surfaces and allowing the A?-specific antibodies to bind to the A?-aggregates, and —detecting the A?-specific antibodies bound to the A?-aggregates by a single particle detection technique, preferably by fluorescence activated cell sorting (FACS); and wherein the amount of A?-specific antibodies detected is compared with the amount in a sample of known AD status.

Abstract: The present invention relates to a vaccine capable to induce production of antibodies directed to PCSK9 in vivo.

Abstract: Disclosed is a method for detecting aSyn-specific antibodies in a biological sample, comprising the following steps: contacting the sample with aSyn-comprising-aggregates and allowing the aSyn-specific antibodies to bind to the aSsyn-comprising-aggregates, and detecting the aSyn-specific antibodies bound to the aSyn-comprising-aggregates by a single particle detection technique, preferably by fluorescence activated cell sorting (FACS).

Abstract: Vaccine comprising a peptide bound to a pharmaceutically acceptable carrier, said peptide having the amino acid sequence (Formula?I) (SEQ?ID?NO:?1) (X1)m(X2)n(X3)oX4X5HPX6, for treating and/or preventing a physical disorder associated with the renin-activated angiotensin system, wherein X1 is G or D, X2 is A, P, M, G, or R, X3 is G, A, H, or V, X4 is S, A, D, or Y, X5 is A, D, H, S, N, or I, X6 is A, L or F, wherein m, n and o are independently 0 or 1 under the premise that when o is 0 m and n are 0 and when n is 0 m is 0, and wherein the peptide is not DRVYIHPF (SEQ ID NO:4).

Abstract: Vaccine comprising a peptide bound to a pharmaceutically acceptable carrier, said peptide having the amino acid sequence (SEQ?ID?NO:?1) (X1)m?(X2)n?(X3)o?X4?X5?H?P?X6 (Formula?I), for treating and/or preventing a physical disorder associated with the renin-activated angiotensin system, wherein X1 is G or D, X2 is A, P, M, G, or R, X3 is G, A, H, or V, X4 is S, A, D, or Y, X5 is A, D, H, S, N, or I, X6 is A, L or F, wherein m, n and o are independently 0 or 1 under the premise that when o is 0 m and n are 0 and when n is 0 m is 0, and wherein the peptide is not DRVYIHPF (SEQ ID NO:4).

Abstract: Disclosed is a method for diagnosing Alzheimer's disease (AD) wherein A?-specific antibodies in a biological sample of a person that is suspected of having AD are detected comprising the following steps: —contacting the sample with A?-aggregates or with particles having A?-aggregate like surfaces and allowing the A?-specific antibodies to bind to the A?-aggregates, and —detecting the A?-specific antibodies bound to the A?-aggregates by a single particle detection technique, preferably by fluorescence activated cell sorting (FACS); and wherein the amount of A?-specific antibodies detected is compared with the amount in a sample of known AD status.

Abstract: Disclosed is a method for detecting A?-specific antibodies in a biological sample comprising the following steps:—contacting the sample with A?-aggregates or with particles comprising A?-aggregate like surfaces and allowing the A?-specific antibodies to bind to the A?-aggregates, and -detecting the A?-specific antibodies bound to the A?-aggregates by a single particle detection technique, preferably by fluorescence activated cell sorting FACS.

Abstract: Vaccine comprising a peptide bound to a pharmaceutically acceptable carrier, said peptide having the amino acid sequence (Formula?I) (SEQ?ID?NO:?1) (X1)m(X2)n(X3)oX4X5HPX6, for treating and/or preventing a physical disorder associated with the renin-activated angiotensin system, wherein X1 is G or D, X2 is A, P, M, G, or R, X3 is G, A, H, or V, X4 is S, A, D, or Y, X5 is A, D, H, S, N, or I, X6 is A, L or F, wherein m, n and o are independently 0 or 1 under the premise that when o is 0 m and n are 0 and when n is 0 m is 0, and wherein the peptide is not DRVYIHPF (SEQ ID NO:4).